CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 86 enrolled
Drug / intervention
Resolute Integrity Zotarolimus eluting stent +3 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02098876
NCT02098876N/ACompleted

Evaluation of WSS and Neointimal Healing Following Percutaneous Coronary Intervention of Angulated Vessels With Resolute® Integrity Zotarolimus Eluting Coronary Stent Compared to XIENCE Xpedition® Everolimus Eluting Coronary Stent

Emory University·interventional·Posted Mar 28, 2014·Updated Sep 9, 2022

In Brief

A clinical study evaluating Resolute Integrity Zotarolimus eluting stent, Xience Xpedition everolimus eluting stent, and 2 other interventions for Coronary Artery Disease. Completed, enrolled 86 participants across 10 sites in 7 countries.

Detailed Summary

Stents are metallic tubular supports placed inside a blood vessel to relieve an obstruction and restore blood flow to the heart muscle. Stents could also be coated with a drug (drug-eluting stents - DES) that improves local healing and inhibits growth of scar tissue within the vessel that otherwise could lead to re-narrowing. This study will evaluate the effects of 2 FDA-approved metallic stents with different designs that may have important effects on regional plaque response and blood flow dynamics immediately after stent deployment and stent healing at 12 months follow up.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina, Japan, Latvia, Serbia, South Korea, Spain, United States
CollaboratorsMedtronic

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 28, 2014
Enrollment StartMay 1, 2014
Primary CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 12.3 years ago

Interventions

Resolute Integrity Zotarolimus eluting stentdevice

PCI with Resolute stent

Xience Xpedition everolimus eluting stentdevice

PCI with Xience stent

Optical Coherence Tomography (OCT)device

Optical coherence tomography (OCT) will be performed at baseline to assess plaque burden prior to and after stent deployment as well as to evaluate stent expansion and stent apposition. OCT will be repeated at one year follow-up to evaluate neo-intimal tissue coverage within the stent and change in plaque area at the stent edges. Offline, manual detection of lumen area and stent area will be performed for each OCT cross-section from baseline and follow up examinations.

Intravascular Ultrasound (IVUS)device

Intravascular ultrasound (IVUS) will be performed at baseline to assess plaque burden prior to and after stent deployment as well as to evaluate stent expansion and stent apposition. IVUS will be repeated at one year follow-up to evaluate neo-intimal tissue coverage within the stent and change in plaque area at the stent edges. Offline, manual detection of lumen area, stent area, vessel area (external elastic membrane) and the media-adventitia interface will be performed for each IVUS cross-section from baseline and follow up examinations.